LVTTF: AI 评分 47/100 — AI 分析 (4月 2026)

Levitee Labs Inc. operates as a multidisciplinary integrative wellness company, providing alternative medicines and psychedelic therapies. The company focuses on treatments for substance use disorders, chronic pain, and mental health conditions through its clinics and pharmacies.

Key Facts: AI Score: 47/100 Sector: Healthcare

公司概况

概要：

Levitee Labs Inc. is a Canadian healthcare company focusing on alternative medicines and psychedelic therapies for substance use disorders and chronic pain, operating clinics and pharmacies. It distinguishes itself through integrative wellness services and electronic prescriptions, competing in the specialty drug manufacturing and mental health treatment sectors.

LVTTF是做什么的？

Levitee Labs Inc., established in 2019 and based in Vancouver, Canada, is a multidisciplinary integrative wellness company focused on providing evidence-based alternative medicines and novel psychedelic therapies. Originally named Fibonacci Capital Corp., the company rebranded to Levitee Labs Inc. in November 2020 to better reflect its evolving mission. The company operates through two segments: Medical Services and Selling Products. The Medical Services segment includes five Levitee Clinics, offering treatments for substance use disorders, chronic pain (such as myofascial pain, fibromyalgia, neuropathy, and chronic regional pain syndrome), hepatitis-C, and mental health conditions. The Selling Products segment encompasses three Levitee Pharmacies in Alberta, providing pharmaceutical services and products. Additionally, Levitee Labs offers electronic prescriptions in the addiction treatment space through BlockMD and wholesales supplements and superfoods under the Earth Circle Organics brand. Levitee Labs aims to integrate alternative and traditional medicine to address unmet needs in mental health and addiction treatment.

LVTTF的投资论点是什么？

Levitee Labs Inc. presents a unique investment opportunity within the evolving landscape of alternative medicine and psychedelic therapies. With a market capitalization of $0.00B and a negative P/E ratio of -0.03, the company is currently not profitable, reflected in its -662.4% profit margin. However, its 39.9% gross margin indicates potential in its core operations. Growth catalysts include the expansion of its clinic network and the increasing acceptance of psychedelic therapies. The company's ability to scale its BlockMD electronic prescription platform and Earth Circle Organics wholesale business could drive revenue growth. Key risks include regulatory hurdles in the psychedelic therapy space and the company's current lack of profitability. Investors should monitor the company's progress in achieving profitability and navigating the regulatory environment.

LVTTF在哪个行业运营？

Levitee Labs operates within the specialty and generic drug manufacturing industry, which is experiencing growth due to increasing demand for alternative and integrative therapies. The market for psychedelic therapies is nascent but rapidly expanding, driven by growing acceptance of their potential in treating mental health conditions. The competitive landscape includes companies like CNNXF, CSTF, GBHPF, INSO, and LTHO, which are involved in various aspects of healthcare and pharmaceutical services. Levitee Labs differentiates itself through its integrated approach, combining clinics, pharmacies, and digital platforms to provide comprehensive wellness solutions.

Drug Manufacturers - Specialty & Generic

Healthcare

LVTTF有哪些增长机遇？

Expansion of Clinic Network: Levitee Labs has the opportunity to expand its Levitee Clinics network across Canada and potentially into the United States. The market for addiction and mental health treatment is substantial, with increasing demand for integrated and alternative therapies. Each new clinic can contribute significantly to revenue growth, with a timeline of opening 2-3 new clinics per year over the next five years. This expansion can be funded through strategic partnerships and capital raises.
Growth of BlockMD Platform: The BlockMD electronic prescription platform offers a significant growth opportunity by streamlining addiction treatment prescriptions. The market for electronic prescriptions is growing rapidly, driven by increased efficiency and convenience. Levitee Labs can expand BlockMD by partnering with other clinics and healthcare providers, creating a broader network and increasing its user base. The timeline for this expansion is within the next 3 years, focusing on integrating with existing healthcare systems.
Development of Psychedelic Therapies: Levitee Labs can capitalize on the growing interest in psychedelic therapies by developing and offering novel treatments for mental health conditions. The market for psychedelic therapies is projected to reach billions of dollars in the coming years, driven by increasing clinical evidence of their effectiveness. Levitee Labs can invest in research and development to create proprietary therapies and establish itself as a leader in this emerging field. This is a longer-term growth opportunity, with a timeline of 5-7 years for regulatory approvals and market entry.
Strategic Partnerships and Acquisitions: Levitee Labs can pursue strategic partnerships and acquisitions to expand its product and service offerings. Partnering with other healthcare providers, technology companies, and research institutions can accelerate its growth and enhance its competitive position. Acquisitions of complementary businesses can provide access to new markets, technologies, and customer bases. The timeline for these partnerships and acquisitions is ongoing, with a focus on identifying synergistic opportunities.
Expansion of Earth Circle Organics: The Earth Circle Organics brand offers an opportunity to expand into the growing market for supplements and superfoods. The demand for natural and organic products is increasing, driven by health-conscious consumers. Levitee Labs can expand its product line, distribution channels, and marketing efforts to reach a broader audience. This expansion can be achieved within the next 2-3 years, focusing on online sales and partnerships with retailers.

Operates five clinics under the Levitee Clinics brand, providing treatments for substance use disorders and chronic pain.
Maintains three pharmacies in Alberta under the Levitee Pharmacies name, expanding its reach in pharmaceutical services.
Offers electronic prescriptions in the addiction treatment space through its BlockMD platform, enhancing accessibility and convenience.
Wholesales supplements and superfoods under the Earth Circle Organics brand, diversifying its revenue streams.
Gross margin of 39.9% suggests potential for profitability as the company scales its operations and optimizes costs.

LVTTF提供哪些产品和服务？

Operates integrative wellness clinics offering treatments for substance use disorders and chronic pain.
Provides pharmaceutical services through its network of pharmacies.
Offers electronic prescriptions for addiction treatment through the BlockMD platform.
Wholesales supplements and superfoods under the Earth Circle Organics brand.
Develops and offers evidence-based alternative medicines.
Explores and develops novel psychedelic therapies for mental health conditions.

LVTTF如何赚钱？

Generates revenue through medical services provided at its clinics.
Earns revenue from the sale of pharmaceutical products at its pharmacies.
Collects fees from electronic prescriptions through the BlockMD platform.
Generates revenue from the wholesale of supplements and superfoods under the Earth Circle Organics brand.

Individuals seeking treatment for substance use disorders.
Patients suffering from chronic pain conditions.
Individuals seeking mental health support and alternative therapies.
Pharmacies and retailers purchasing supplements and superfoods.
Healthcare providers utilizing the BlockMD electronic prescription platform.

Integrated Service Model: Combines clinics, pharmacies, and digital platforms for comprehensive care.
Proprietary Technology: BlockMD platform provides a unique electronic prescription solution.
Brand Recognition: Established brands like Levitee Clinics and Earth Circle Organics.
Expertise in Alternative Therapies: Focus on evidence-based alternative medicines and psychedelic therapies.

什么因素可能推动LVTTF股价上涨？

Upcoming: Expansion of the Levitee Clinics network into new geographic locations by Q4 2026.
Ongoing: Development and potential regulatory approval of novel psychedelic therapies for mental health conditions.
Ongoing: Growth of the BlockMD electronic prescription platform through partnerships with other healthcare providers.
Ongoing: Expansion of the Earth Circle Organics product line and distribution channels.
Upcoming: Potential strategic partnerships or acquisitions to expand product and service offerings by mid-2027.

LVTTF的主要风险是什么？

Potential: Regulatory hurdles and changing regulations in the psychedelic therapy space.
Ongoing: Competition from established pharmaceutical companies and healthcare providers.
Potential: Economic downturns affecting consumer spending on alternative therapies.
Potential: Negative publicity or safety concerns related to psychedelic therapies.
Ongoing: Limited liquidity and potential price volatility due to trading on the OTC market.

LVTTF的核心优势是什么？

Integrated service model combining clinics, pharmacies, and digital platforms.
Focus on alternative medicines and psychedelic therapies.
Established brands like Levitee Clinics and Earth Circle Organics.
Proprietary technology with the BlockMD electronic prescription platform.

LVTTF的劣势是什么？

Currently not profitable, with a negative profit margin.
Reliance on regulatory approvals for psychedelic therapies.
Limited market capitalization and liquidity.
Exposure to competition from larger and more established healthcare providers.

LVTTF有哪些机遇？

Expansion of clinic network across Canada and the United States.
Growth of the BlockMD platform through partnerships and integrations.
Development and commercialization of novel psychedelic therapies.
Strategic partnerships and acquisitions to expand product and service offerings.

LVTTF面临哪些威胁？

Regulatory hurdles and changing regulations in the psychedelic therapy space.
Competition from established pharmaceutical companies and healthcare providers.
Economic downturns affecting consumer spending on alternative therapies.
Negative publicity or safety concerns related to psychedelic therapies.

LVTTF的竞争对手是谁？

Cannex Capital Holdings Inc — Focuses on cannabis-related investments and operations. — (CNNXF)
Code Smart Holdings Inc — Provides technology solutions for healthcare compliance. — (CSTF)
Global Hemp Group Inc — Focuses on hemp cultivation and processing. — (GBHPF)
Inspirato Incorporated — Provides luxury travel and vacation services. — (INSO)
Lithium Corporation — Explores and develops lithium properties. — (LTHO)

Key Metrics

MoonshotScore: 47/100

Company Profile

CEO: David Bentil
Headquarters: Vancouver, CA
Founded: 2021

AI Insight

AI analysis pending for LVTTF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Levitee Labs Inc. do?

Levitee Labs Inc. operates as a multidisciplinary integrative wellness company, focusing on providing evidence-based alternative medicines and novel psychedelic therapies. The company operates through two segments: Medical Services and Selling Products. The Medical Services segment includes clinics offering treatments for substance use disorders, chronic pain, and mental health conditions. The Selling Products segment encompasses pharmacies and the wholesale of supplements and superfoods. Additionally, Levitee Labs offers electronic prescriptions through its BlockMD platform, aiming to provide comprehensive and accessible wellness solutions.

What do analysts say about LVTTF stock?

As of 2026-03-17, there is no readily available analyst consensus on LVTTF stock due to its OTC listing and limited coverage. Key valuation metrics include a negative P/E ratio of -0.03 and a profit margin of -662.4%, indicating current lack of profitability. However, the company's 39.9% gross margin suggests potential for improvement. Growth considerations include the expansion of its clinic network, the development of psychedelic therapies, and the growth of its BlockMD platform. Investors should conduct their own due diligence and consider the risks associated with OTC stocks.

What are the main risks for LVTTF?

The main risks for Levitee Labs Inc. include regulatory hurdles in the psychedelic therapy space, competition from established pharmaceutical companies and healthcare providers, and economic downturns affecting consumer spending on alternative therapies. Additionally, negative publicity or safety concerns related to psychedelic therapies could impact the company's reputation and growth prospects. As an OTC-listed stock, LVTTF also faces risks related to limited liquidity and potential price volatility. Investors should carefully consider these risks before investing in Levitee Labs Inc.